A Mechanistic Study of the Effects of LY518674 on High-Density Lipoprotein Cholesterol (HDL-C) Metabolism
Status:
Completed
Trial end date:
2006-11-01
Target enrollment:
Participant gender:
Summary
Agents that increase HDL-C via reverse cholesterol transport could provide a new therapeutic
option for the prevention of atherosclerotic cardiovascular disease. The investigators
propose to investigate the effects of LY518674 on components that may likely affect
atherogenesis in patients with the metabolic syndrome including HDL-C metabolism and reverse
cholesterol transport pathways, the inflammatory response, and oxidative stress in human
subjects.
As an agonist of the nuclear peroxisome proliferator activated receptor (PPAR) alpha,
LY518674 may affect the transcription of genes that encode various proteins involved in
atherogenesis. This study will explore the consequences of altered transcription such as
changes in messenger ribonucleic acid (mRNA) and protein levels as well as protein activity.